These Are a Few of Our Favorite IoT: NIST Finalizes Internet of Things Cyber Guidance
Client Alert | 1 min read | 07.02.19
NIST has finalized Internet of Things (IoT) risk management guidance, which derived from a draft publication. The guidance informs government agencies how to understand and manage IoT risks throughout device lifecycles. Industry can anticipate government focus on three high-level goals:
- Device security;
- Data security; and
- Individual privacy.
The publication highlights three differences between managing risks for IoT devices and conventional information technology devices:
- IoT devices interact with the physical world differently than conventional devices;
- IoT devices cannot be accessed and monitored the same as conventional devices; and
- The availability and effectiveness of cybersecurity and privacy capabilities are different for IoT devices than conventional devices.
While not mandatory, the guidance provides useful considerations for IoT cybersecurity and privacy risk management.
Contacts

Partner and Crowell Global Advisors Senior Director
- Washington, D.C.
- D | +1.202.624.2698
- Washington, D.C. (CGA)
- D | +1 202.624.2500
Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 3 min read | 04.17.26
Client Alert | 2 min read | 04.16.26
Client Alert | 4 min read | 04.16.26
ROI Tracking as Mens Rea? Novartis Ruling Reframes AKS Pleading Risk


